Interim Vytorin data not forthcoming until 2012; Japan's high court upholds Aricept patent;

@FiercePharma: Barclays downgrades Pfizer, cuts target to $19: Not impressed enough with near-term pipeline. News | Follow @FiercePharma

> Interim analysis of the data in Merck's ($MRK) Vytorin outcomes trial has been postponed to 2012, rather than late this year. The full trial is still expected to be wrapped in 2013. Report

> Japan's top court has upheld the patent on Eisai's Aricept treatment for Alzheimer's disease, confirming its protection through June 2013. Item

> Sanofi's ($SNY) U.S. unit has teamed up with Barry Manilow on an atrial fibrillation awareness campaign; the French drugmaker's Multaq drug is an AFib treatment. Report

> Barclays Capital downgraded Pfizer stock ($PFE) to "equalweight" and cut its price target slightly to $19, citing perceived shortcomings in the company's near-term pipeline. More

> Boehringer Ingelheim's planned $382 million expansion in Ridgefield, CT, is moving forward with two new building projects. Story

> SuperGen changed its name to Astex Pharmaceuticals after closing its acquisition of Astex Therapeutics; its ticker will change to ASTX from SUPG. Piece

Biotech News

@FierceBiotech: Patch works as a method to deliver fenretinide to the mouth for oral cancers. Patch is applied to inner cheek. Item | Follow @FierceBiotech

@JohnCFierce: Details on our Boston breakfast with Vertex's Peter Mueller, Biogen's Doug Williams, Omid Farokhzad and Steven Knight. More | Follow @JohnCFierce

@RyanMFierce: My quick take on Vertex CEO's tiff with analyst: Sounds brave but not sure if it's in the best interest of $VRTX shareholders. We'll see... | Follow @RyanMFierce

@MaureenFierce: Researchers develop micromotor which could one day swim through a patient's blood stream, repair body. Story | Follow @MaureenFierce

> Vertex CEO Emmens offers analyst a barbed review of his own. News

> Abbott deals beef up late-stage platform of blockbuster contenders. Report

Medical Device News

> Boston Sci snags J&J exec as next CEO. News

> Intersect ENT sees positive data on Propel from pivotal trial. Article

> Zimmer gets pediatric clearance for spinal fixation system. Piece

> RF Surgical closes $12M round. More

> Keltjens tapped as Endosense president, CEO. Story

> Miracor raises $10M in Series B. News

Drug Delivery News

> Adenosine used to break through BBB, deliver large-molecule drugs. Report

> Patch works as delivery method for oral cancer. Article

> Nasal delivery of insulin appears to help Alzheimer's patients. Story

> Marina Biotech pins new hopes on patents for RNAi revival. Piece

> 'Trojan Horse' sneaks into cells using tumor's own defense mechanism. Item

> Smuggling drugs across the blood-brain barrier. Story

And Finally... Drug-resistant tuberculosis is spreading rapidly, WHO says. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.